Form Type: 4

SEC EDGAR Link
Accession Number:0000886163-21-000071
Date:2021-05-11
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
Original Submission Date:

Reporting Person:

KOZARICH JOHN W
3911 SORRENTO VALLEY BOULEVARD, STE 110
SAN DIEGO, CA 92121

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-05-11 M 4,835 a $10.12 34,543 direct
COMMON STOCK 2021-05-11 F 391 d $128.56 34,152 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
NON-QUALIFIED STOCK OPTION (RIGHT TO BUY) 10.12 2021-05-11 deemed execution date M 4,835 (d) 2012-06-01 common stock 4,835 $10.12 0 direct
Footnotes
IDfootnote
f1 represents shares withheld by the issuer in payment of the exercise price of options.
f2 acquired by a grant of the board of directors of the company at their annual meeting on june 01, 2011, and fully vested on the first anniversary of the grant date.

Elevate your investments